Diabetes currently affects 24 million individuals in the United States alone. The incidence of adult onset or Type II diabetes has increased 15 percent over the last two years, targeting nearly a quarter of individuals over 60. Worldwide, the incidence of diabetes is predicted to double by 2030, accounting for nearly 370 million people. By any measure, this disease has reached epidemic proportions.
Key to the development of either Type 1 or Type II diabetes is the inability of the pancreas to produce enough insulin, either because the number of insulin producing islet cells is too low, or because the target cells become deaf to insulin's message. Salk scientists are working on understanding the molecular and genetic basis of the disease to advance the development of possible future treatments and perhaps a cure.
One injection stops diabetes in its tracks
July 16, 2014
Salk scientists crack riddle of important drug target
December 2, 2013
More than 3,000 epigenetic switches control daily liver cycles
December 10, 2012
Tweaking a gene makes muscles twice as strong
November 18, 2011
How cells running on empty trigger fuel recycling
December 23, 2010
September 13, 2011
Salk Institute for Biological Studies
La Jolla, California
July 16, 2014
In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery by Salk scientists, published today in the journal Nature, could lead to a new generation of safer, more effective diabetes drugs. Read more>>
May 17, 2012
It turns out that when we eat may be as important as what we eat. Scientists at the Salk Institute for Biological Studies have found that regular eating times and extending the daily fasting period may override the adverse health effects of a high-fat diet and prevent obesity, diabetes and liver disease in mice. Read more>>
April 08, 2012
In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose—the simple sugar that is the source of energy in human cells and the central player in diabetes. Read more>>
April 24, 2011
Humans are built to hunger for fat, packing it on during times of feast and burning it during periods of famine. But when deluged by foods rich in fat and sugar, the modern waistline often far exceeds the need to store energy for lean times, and the result has been an epidemic of diabetes, heart disease and other obesity-related problems.
Now, scientists at the Salk Institute for Biological Studies have identified the linchpin of fat metabolism, a protein known as fibroblast growth factor 1 (FGF1), which may open new avenues in the treatment of diabetes. Read more>>>
May 12, 2011
A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.
Their findings, published in the May 13, 2011, issue of the journal Cell, revealed a crucial role for so called histone deacetylases (HDACs), a group of enzymes that is the target of the latest generation of cancer drugs. HDACs get sugar production rolling when blood glucose levels run low after prolonged periods of fasting or during the night. Read more>>
September 13, 2011
According to the latest figures, nearly 25.8 million children and adults in the United States have diabetes, 7 million of those remain undiagnosed and an estimated 79 million people are at risk of developing the condition. It’s the sixth leading cause of death, and it costs our country more than $116 billion annually in direct medical costs. What is more, the Centers for Disease Control estimate that if current trends continue, by 2050, the number of Americans with diabetes will triple, with a staggering 1 in 3 affected.